T2 Biosystems, Inc. (TTOO) News

T2 Biosystems, Inc. (TTOO): $1.67

0.06 (+3.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter TTOO News Items

TTOO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TTOO News Highlights

  • TTOO's 30 day story count now stands at 2.
  • Over the past 26 days, the trend for TTOO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest TTOO News From Around the Web

Below are the latest news stories about T2 BIOSYSTEMS INC that investors may wish to consider to help them evaluate TTOO as an investment opportunity.

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results

Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2022. Full Year 2022 and Recent Highlights (unaudited) Achieved full year 2022 total revenue of $22.3 million, including prod

Yahoo | January 23, 2023

T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.

LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health care performance improvement company in the country, has been extended through March 31, 2024. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2C

Yahoo | December 28, 2022

T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy

LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America. "We are grateful to these distinguished authors for reinforcing the CDC’s call for adoption and implementation of early and accurate microbial diagnosis to guide target

Yahoo | December 8, 2022

T2 Biosystems Third Quarter 2022 Earnings: Misses Expectations

T2 Biosystems ( NASDAQ:TTOO ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.68m (down 51% from 3Q...

Yahoo | November 16, 2022

T2 Biosystems Announces Third Quarter 2022 Financial Results

Achieves record quarterly sepsis and related revenue and advances product pipelineLEXINGTON, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the third quarter ended September 30, 2022. Recent Commercial and Financial Highlights Achieved third quarter total revenue of $3.7 million, including product revenue of $2.6 million.A

Yahoo | November 10, 2022

T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement

LEXINGTON, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”). The amendment extends both the interest-only period and the maturity date by one year from December 30, 2023 to December 30, 2024. No other material amendments were made to the Term Loan Agreement. “We conti

Yahoo | November 10, 2022

T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

LEXINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, New York. Management is scheduled to present on Thursday, November 17, 2022, at 2pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Inves

Yahoo | November 9, 2022

HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize

LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation (“Cohen Foundation”) have selected T2 Biosystems as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (“LymeX”) prize competition to accelerate the development of Lyme d

Yahoo | November 7, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

LEXINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on October 31, 2022 informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market. As previousl

Yahoo | November 1, 2022

T2 Biosystems to Report Third Quarter 2022 Financial Results on November 10, 2022

LEXINGTON, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2022 after market close on Thursday, November 10, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and

Yahoo | October 31, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5636 seconds.